Elegen and Nutcracker Therapeutics launched a pilot program integrating their platforms to enable industry-first fully synthetic, cell-free manufacturing of RNA-based personalized cancer therapeutics (PCTs). The collaboration combines Elegen’s GMP-ready cell-free DNA template production with Nutcracker’s rapid, scalable RNA synthesis system, aiming to overcome conventional production bottlenecks such as bacterial contamination risks, slow processes, and high costs. The partnership promises faster turnaround times (~3 weeks from design to drug product), improved scalability, and democratized access to PCTs, potentially accelerating treatment delivery for cancer patients.